Jalan, Manisha http://orcid.org/0000-0002-4467-4934
Sharma, Aman http://orcid.org/0000-0003-1017-8307
Pei, Xin http://orcid.org/0000-0001-9961-6152
Weinhold, Nils
Buechelmaier, Erika S.
Zhu, Yingjie http://orcid.org/0000-0003-1849-6019
Ahmed-Seghir, Sana
Ratnakumar, Abhirami
Di Bona, Melody http://orcid.org/0000-0002-8853-2604
McDermott, Niamh
Gomez-Aguilar, Joan
Anderson, Kyrie S.
Ng, Charlotte K. Y.
Selenica, Pier
Bakhoum, Samuel F.
Reis-Filho, Jorge S.
Riaz, Nadeem http://orcid.org/0000-0001-9873-5862
Powell, Simon N. http://orcid.org/0000-0002-8183-4765
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA247749)
American Association for Cancer Research (20-40-64-JALA)
Article History
Received: 15 December 2023
Accepted: 15 August 2024
First Online: 5 September 2024
Competing interests
: S.F.B. owns equity in, receives compensation from, and serves as a consultant for and serves on the Scientific Advisory Board (SAB) and Board of Directors (BOD) of Volastra Therapeutics Inc and he serves on the scientific advisory board of Meliora Therapeutics. J.S.R.-F. reports current employment at AstraZeneca and stocks in AstraZeneca, Repare Therapeutics, Paige.AI; J.S.R.-F. previously held a fiduciary role in Grupo Oncoclinicas and was a consultant with Goldman Sachs Merchant Banking, Bain Capital, Repare Therapeutics, Paige.AI, Volition Rx and MultiplexDx. S.N.P. reports consulting fees from the following companies outside the scope of this study: Varian Medical Systems, Philips Healthcare and AstraZeneca, as well as research funding from Philips Healthcare and Varian Medical Systems. The remaining authors declare no competing interests.